Neoadjuvant gemcitabine/cisplatin alone, with nivolumab, or with nivolumab plus linrodostat in cisplatin-eligible muscle-invasive bladder cancer. A three-arm Phase 3 test of whether IDO1 inhibition adds anything to PD-1 + chemo — the cleanest possible test of the coverage principle in any trial currently on the scorecard.
Linrodostat (BMS-986205) is an oral IDO1 inhibitor. IDO1 modulates the same immune-suppression pathway that PD-1 already addresses — both work to release T cells from suppression at the effector encounter step. ECHO-301 (pembrolizumab ± epacadostat in melanoma, n=706) tested an analogous combination in a different cancer type and found that IDO1 inhibition adds nothing to PD-1 blockade. There is no structural reason to expect a different outcome in bladder cancer.
What makes ENERGIZE unusually clean is the three-arm design. Arm A is gemcitabine/cisplatin alone. Arm B is gemcitabine/cisplatin + nivolumab. Arm C is gemcitabine/cisplatin + nivolumab + linrodostat. The framework's prediction is that Arm B will significantly outperform Arm A — PD-1 adds a genuinely new step (encounter) to chemotherapy alone, which is what the existing immuno-oncology literature shows. But Arm C will be statistically indistinguishable from Arm B, because IDO1 is redundant with the PD-1 step already present in Arm B. The IDO1 arm adds drug burden without adding coverage.
This is the only trial currently on the Encounter scorecard where the coverage principle can be tested in a single data table by comparing three arms ordered by step coverage: zero added steps (chemo alone), one added step (chemo + PD-1), one added step plus a duplicate (chemo + PD-1 + IDO1). If the framework is right, the differences look like (B > A, large) and (C ≈ B, small).
Each row below is a falsifiable claim with a value range. If the trial reports out within these ranges, the prediction is a hit. If it reports outside them in the named direction, the prediction is a miss.
| Metric | Predicted value |
|---|---|
| Arm A pCR (gemcitabine/cisplatin alone) | Baseline |
| Arm B pCR (gem/cis + nivo) | Significantly above Arm A |
| Arm C pCR (gem/cis + nivo + linrodostat) | Statistically indistinguishable from Arm B |
| Δ(C − B) | 0–5 percentage points (ns) |
| Δ(B − A) | Meaningfully positive, statistically significant |
The critical test: the prediction holds if and only if (B > A) AND (C ≈ B). If Arm C is significantly better than Arm B by more than 5pp, the framework's claim that IDO1 is redundant with PD-1 is wrong. If Arm B is not significantly better than Arm A, the framework's broader claim about checkpoint blockade adding a step to chemotherapy is wrong (and most of immuno-oncology is wrong with it). The latter would be a much larger anomaly than the former.
The structural reasoning behind the call — which steps in the immune cycle each drug covers, where the prediction would break, what it means for the design of follow-on trials in adjacent indications — is in the full report. The full report also includes the framework's per-metric reasoning for each row in the table above and the structural mapping for the trial's arms.
Fill the form to start the purchase. We reply within two business days with the price, scope, and a Stripe invoice. The full report is delivered as a PDF on payment.
* Trial cost estimate: ~1,200 patients × $40K median per patient (oncology Phase 3, US sites, Moore et al. 2018 cross-sectional analysis of 2015–2017 trials). Order-of-magnitude only — actual trial cost is not publicly disclosed.